Q2FY27 Results: 18 firms report on Oct 17, 2026

Results day brings banks and midcaps together

A busy Q2FY27 results calendar is in focus on Saturday, with 18 listed companies scheduled to announce July to September earnings. The list spans large private banks, state-owned lenders, a cement company, and a travel-tech platform, alongside smaller manufacturing and speciality businesses. Investors typically track such clustered result days for sector cues, management commentary, and any changes in near-term guidance. In banking, market attention usually centres on growth, asset quality and margins, while non-financials are watched for demand trends and cost pressures.

Alongside the broader results list, Bajaj Healthcare has drawn attention due to multiple recent disclosures related to its results schedule and an upcoming earnings call. The company has also reported its latest available quarterly performance for Q1 FY27 and referenced earlier filings around its reporting process.

Companies announcing Q2 results today

The companies named as scheduled to announce Q2FY27 (July to September) results on Saturday include:

• HDFC Bank
• ICICI Bank
• AXIS Bank
• Yes Bank
• IDBI Bank
• Central Bank of India
• Punjab & Sind Bank
• India Cements
• Le Travenues Technology (Ixigo)
• Rossari Biotech
• Bajaj Healthcare
• Kross
• Cupid Breweries and Distilleries
• Midland Polymers
• Indo Cotspin
• TGB Banquets and Hotels
• Gagan Gases
• Hemo Organic

This list mixes high-liquidity names in financials with smaller companies where disclosures such as board meeting schedules and earnings call notices often drive investor attention.

Banking names on the docket

Among the scheduled reporters, HDFC Bank, ICICI Bank and AXIS Bank are the largest private-sector names mentioned, while Yes Bank also features in the list. On the public-sector side, IDBI Bank, Central Bank of India, and Punjab & Sind Bank are included. With multiple banks reporting on the same day, investors typically compare trends across peers rather than looking at one standalone print.

The article context does not provide quarter numbers for these banks, but it confirms the schedule and the breadth of reporting. Because the list spans both private and public-sector lenders, results day may also be used by the market to contrast operating performance and any management commentary that accompanies filings.

Bajaj Healthcare: board meeting and earnings call details

Bajaj Healthcare Limited (BAJAJHCARE) is highlighted with a board meeting date and an earnings call schedule. The company indicated its board meets on 17 Oct 2026 to consider Q2 FY27 results for the July to September 2026 quarter. Separately, the company is set to hold an earnings call for Q2 and H1 FY27 on October 19, 2026 at 5:00 PM IST.

The earnings call is to be conducted with Managing Director Anil Jain and CFO Rohan Parekh. The schedule was announced in a filing dated October 14, 2026, referencing an earlier intimation from October 9, 2026. The company has also previously held an earnings call on July 21, 2026 at 4:00 PM IST to discuss Q1 FY27 results under Regulation 30 of SEBI (LODR) Regulations, 2015, with the same senior management participants named.

What Bajaj Healthcare last reported (Q1 FY27)

For context ahead of Q2 FY27 disclosures, the latest reported quarter cited is Q1 FY27. Bajaj Healthcare’s revenue was ₹166 crore in Q1 FY27, up 11.4% year-on-year and 8.5% quarter-on-quarter. The company’s net profit was ₹14.0 crore, up 16.7% year-on-year, and its operating margin was 17.5%.

The text also provides the base comparison numbers for Q1 FY26: revenue of ₹149 crore and net profit of ₹12 crore, against which the Q1 FY27 growth figures are described. No analyst estimate for the upcoming quarter is cited, and the context explicitly notes that no revenue or profit figure should be assumed for the Q2 FY27 quarter.

Regulatory disclosures and the “results date not confirmed” issue

Within the provided context, there is also a repeated note that the Bajaj Healthcare Q2 results date for FY27 is not confirmed as of 9 September 2026, stating that the company had not filed a board meeting intimation with NSE or BSE at that time. It also explains the regulatory framework: listed companies in India must publish quarterly results within 45 days of the quarter end, placing an outer deadline of 14 November 2026 for the September 2026 quarter.

At the same time, the content includes later-dated information that the board meets on 17 Oct 2026 to consider Q2 FY27 results, and it includes an earnings call schedule for Oct 19, 2026. Read together, the timeline indicates the date was not public as of early September, and subsequent filings and disclosures later in October provided specific scheduling details.

Recent corporate update: DCGI approval

Bajaj Healthcare also reported that it has received final approval from the Drug Controller General of India (DCGI) to manufacture and market Cenobamate API and Tablets. The context does not include commercial timelines or revenue impact, but it is presented as a recent corporate announcement relevant to the company’s product and regulatory progress.

Earlier FY26 references in the disclosures

The context includes references to earlier FY26 performance and approvals. Bajaj Healthcare’s board approved audited standalone results for the quarter and year ended March 31, 2026, and it also references adoption of audited financial statements for the year ended March 31, 2026.

A separate FY26 data point cited is that the company reported a Q4 net loss of ₹19.4 crore compared with a profit of ₹11.2 crore year-on-year, with quarterly revenue at ₹153 crore versus ₹154 crore year-on-year. These figures are presented as historical context and are not linked to Q2 FY27 expectations.

The article text also cites a separate set of historical results: Q2 FY26 revenue from operations of ₹1,470.49 crore, up 13.04% year-on-year, and PAT of ₹1,110.92 crore, up 17.37%. For H1 FY26, it cites revenue of ₹2,967.51 crore and PAT of ₹2,294.29 crore, and notes an EPS of ₹3.53 for Q2 FY26. These are included as stated in the provided material.

Stock price snapshot around the Oct 17 disclosure

A corporate-action style table in the provided text gives a price snapshot for Bajaj Healthcare around the quarterly result announcement date.

This table indicates the last traded price (LTP) at the time of announcement and on the record date, as provided.

Key factual summary for Bajaj Healthcare

What investors will track next

For the broader set of 18 companies scheduled to report, the next updates will come through official quarterly result filings and, where announced, earnings calls and exchange intimations. For Bajaj Healthcare, the immediate sequence is the board consideration of Q2 FY27 results followed by the scheduled earnings call on October 19.

The disclosures also underline how results schedules become public in India: through exchange intimations of board meetings and subsequent filings. Where a date is not yet supported by such filings, the statutory deadline provides the boundary, but it is not an expected date by itself.

Conclusion

Q2FY27 results day brings a wide set of companies to the market’s attention, led by large banks and supported by several midcap and smallcap names. Bajaj Healthcare stands out for its documented schedule of a board meeting on Oct 17 and an earnings call on Oct 19, alongside Q1 FY27 performance and a recent DCGI approval update. The next confirmed steps are the companies’ official result filings and, for Bajaj Healthcare, management commentary during the scheduled call covering Q2 and H1 FY27.